NCT06641609 - A Phase I Study of CFT8919 in Patients With Advanced NSCLC | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

December 9, 2025

Study Completion Date

April 3, 2026

Conditions

Non-Small Cell Lung Cancer With EGFR Mutation

Interventions

DRUG

Dose-Escalation (Phase Ia) CFT8919 capsule

Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.

DRUG

Dose-Expansion (Phase Ib) CFT8919 capsule

Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.

DRUG

Cohort-Expansion (Phase Ic) CFT8919 capsule

Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.

Trial Locations (1)

浙江省杭州市拱墅区半山东路1号的英文翻译为： No. 1 Banshan East Road, Gongshu District, Hangzhou, Zhejiang Province, China, Hangzhou